Opinion & analysis

Countdown To Transition: US FDA Says 91 Drugs Will Become Biologics In March 2020

A Pink Sheet infographic shows how insulins account for the largest category of transition products, with 27 NDAs that will be deemed BLAs in six months as the FDA is addressing the transition of authorized generic insulins to regulation under the PHS act.

Countdown To Transition: US FDA Says 91 Drugs Will Become Biologics In March 2020

Cosmetic Preservatives Crisis Creeping Into CIR Program

Contamination In Common OTC Antacid Adds To FDA’s API Impurity Concerns

Commission Would Back Limited Expansion Of Products Covered By MDR Grace Period

Commission Looks Set To Expand MDR Extension So Notified Bodies Can Focus On High-Risk Devices

Commission Addresses Non-EU/EEA Authorities To Set Record Straight On New EU Regs

Colgate/Tom’s Of Maine Pays Back Unilever For ‘Naturally Dry’ Loss

CMS Actively Looking For New Reimbursement Pathway For Innovative Devices

CEO-To-Worker Pay Ratios Averaged 150-1 At Six Top Medtech Companies In 2017

Cell And Gene Therapy Logistics Requires Early Planning

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

Cannabis Industry Taking Legal Action Against EU Regulators Over CBD Novel Food Classification

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?